ArticleInternational ophthalmology2025
Choroidal vascular index alterations in branch retinal vein occlusion: a comparative analysis of anti-VEGF and steroid implants.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim was to evaluate the effects of anti-VEGF and dexamethasone (DEX) implants on choroidal vascular structures in eyes with branch retinal vein occlusion (BRVO).
methodsEyes with temporal BRVO, unaffected fellow eyes, and age- and gender-matched healthy control eyes were retrospectively analyzed. Swept-source optical coherence tomography (SS-OCT) images were collected initially and at the 12-month follow-up visit. Choroidal vascularity index (CVI), choroidal thickness (CT), and central macular thickness (CMT) were measured. Demographic characteristics, treatment modalities, and best-corrected visual acuity (BCVA) were recorded.
resultsThe study involved 305 eyes: 104 with BRVO, 104 healthy fellow eyes, and 97 eyes from healthy controls. Initially, BRVO eyes had lower CVI than fellow eyes and controls (p = 0.032, p = 0.001, respectively). CT was lower in BRVO eyes compared to fellow eyes and controls. Among BRVO eyes, 50 received DEX implants, 54 received anti-VEGF treatment. Significant CVI decrease at 12 months was seen in the anti-VEGF group (p = 0.014), while it remained similar in the DEX implant group (p = 0.619). No difference was observed among anti-VEGF agents.
conclusionThe study primarily showed how different treatment approaches affected choroidal parameteres in a condition largely triggered by hypoxia. It suggested the use of CVI as a prognostic indicator to monitor anti-VEGF drug treatment in BRVO patients.
Indexed as
Identifiers
41134384What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.